ArticleMolecular biology reports2026
MitoTEMPO modulates trigeminal activation and mitochondrial biogenesis in a nitroglycerin-induced migraine model.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundMigraine is a disabling neurovascular disorder in which neuroinflammation, trigeminal activation, and mitochondrial dysfunction play central roles. Mitochondria-targeted antioxidants such as mitoTEMPO may modulate these mechanisms; however, their effects in nitroglycerin (NTG)-induced migraine models remain unclear. This study investigated the effects of mitoTEMPO on mitochondrial biogenesis, fusion-fission dynamics, trigeminal activation, and inflammation in the trigeminal ganglion in an NTG-induced migraine model. METHODS AND
resultsThirty male Sprague-Dawley rats were allocated to control, mitoTEMPO (M), NTG, M + NTG (concomitant administration of mitoTEMPO with NTG), and NTG + M (delayed administration of mitoTEMPO following NTG exposure) groups (n = 6/group). Serum TNF-α levels were measured by ELISA; trigeminal c-Fos, mitofusin-1 (Mfn1), nuclear respiratory factor (NRF1), and mitochondrial transcription factor A (TFAM) protein levels were assessed by Western blot, while NADH-ubiquinone oxidoreductase chain 1 (ND1), TFAM, NRF1, Mfn1, and peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α) mRNA expressions were analyzed by RT-PCR. NTG administration significantly increased serum TNF-α levels and trigeminal c-Fos expression, confirming neuroinflammation and nociceptive activation. Concomitant mitoTEMPO administration attenuated c-Fos expression, whereas delayed administration had no effect, indicating a timing-dependent response. Compared with the NTG group, mitoTEMPO-treated NTG groups exhibited higher Mfn1, NRF1, and TFAM protein levels. At the transcriptional level, no differences were observed in ND1, TFAM, or NRF1 expression; however, Mfn1 mRNA was increased in the NTG group, and PGC-1α expression was significantly upregulated in the NTG + M group, consistent with a delayed mitochondrial biogenesis response.
conclusionsThese findings suggest that NTG induces trigeminal activation and inflammation with limited acute effects on mitochondrial biogenesis, while mitoTEMPO modulates these processes in a phase-dependent manner.
Indexed as
Identifiers
42113070What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.